Endocrine Abstracts

IntroductionAIP is a predisposing gene for GH/PRL-secreting PitNETs. Clinically non-functioning PitNETs (NFPT) occasionally occur in the setting of AIP germline mutations, sometimes arising from Pit-1 lineages. However, AIP overexpression has been observed in unselected NFPT and associations with the gonadotroph phenotype and/or tumour aggressiveness were suggested. We wished to evaluate the significance of AIP expression in gonadotroph tumours defined b...

IntroductionThere is no consensus about biological targets in patients with central hypothyroidism (CH). The main objective of this work was to characterize our patients with CH.DesignWe conducted a retrospective study at the University Hospital of Amiens. In our center, patients with CH are considered “well substituted” if the free thyroxine (FT4) is in the upper half of the reference interval and ...

ObjectiveThe objective of this systematic review was to assess the incidence of growth, new pituitary endocrinopathies, and the incidence of surgery and/or radiotherapy in conservatively treated non-functioning pituitary adenomas/incidentalomas (NFPAs/NFPIs).MethodA bibliographical search of Embase and Pubmed was conducted in order to identify eligible studies.Results<p class="abste...

IntroductionThyrotropinoma is a rare pituitary tumor ( <2% of pituitary adenomas) arising from PIT1-lineage cells, which expresses and secrete TSH. In most cases, the etiology is unknown but rare cases have been described to arise in context of MEN 1 syndrome. Diagnosis is often delayed by confusion with primary hyperthyroidism, which determine the tumor to be already large and invasive at the time of diagnosis. GH and prolactin cosecretion is an increas...

Patients with Cushing’s syndrome have a poor quality of sleep. However, little is known about their timing of sleep as regulated by the circadian clock, the so called-chronotype. Considering that patients with Cushing’s syndrome lose their rhythmic circadian cortisol secretion and that corticosteroids act as synchronizer of the circadian clock in cells, aim of the study was to determine whether patients with Cushing’s syndrome alter the timing of their sleep com...

BackgroundImproved patient-reported outcomes (PROs) are increasingly becoming a key treatment objective in acromegaly. Validated PROs were used to assess disease and treatment burden in the MPOWERED phase 3 trial in acromegaly, which also assessed safety and efficacy of oral octreotide capsules (OOC; MYCAPSSA®) compared to injectable SRLs (iSRLs).MethodsEligible patients had acromegaly diagnosis, biochem...

IntroductionHepcidin, main body iron regulator protein, decreases iron concentration available for erythropoiesis. Oppositely, excessive erythropoiesis in acromegaly patients (increased GH and IGF-1), may inhibit hepcidin production. GH stimulates bone marrow, whereas IGF-1 receptors are expressed in erythrocytes. Exogenous GH administration in healthy subjects reduced hepcidin level. The role of hepcidin in iron metabolism of acromegaly patients has not...

BackgroundCushing’s disease (CD) is caused by high levels of blood cortisol resulting from excess secretion of adrenocorticotropic hormone (ACTH) from an anterior pituitary corticotroph adenoma. Clinical manifestations include diabetes, hypertension, osteoporosis, and depression. If untreated, CD has an increased mortality of five-fold owing to cardiovascular comorbidities, stroke or raised vulnerability to infection. Currently, transsphenoidal surg...